TRADE NEWS: Agilent Technologies, Cell Line Genetics Collaborate on High-Throughput Cell-Line Characterization Services for Regenerative Medicine, Cancer Researchers
SANTA CLARA, Calif.--(BUSINESS WIRE)--Agilent Technologies Inc. (NYSE: A) today announced a collaboration with Cell Line Genetics, Inc., a leading provider of cell-line characterization and quality assurance services. CLG will develop high-throughput, genomic characterization workflows to confirm and monitor the integrity of cell lines for translational and regenerative medicine research. The workflows will be based upon Agilent’s custom, targeted CGH+SNP microarrays and SureFISH technology.
“For example, we can fortify our arrays in regions that we have identified as ‘integrity critical’ for even greater sensitivity. It allows us to easily design proprietary arrays and assays to support our customer’s research and translational needs.”
“Cell Line Genetics customers in the regenerative medicine research market include leading research institutions, biotechnology and pharmaceutical companies,” said Victor Fung, Agilent’s senior director of Global Marketing for the Genomics Solutions Division. “These diverse customers will benefit from services better tailored to meet their needs. In addition, Cell Line Genetics can better control operating costs because targeted array CGH designs can focus probe density where it matters most, enabling much faster data interpretation than SNP microarrays. Speed of analysis is particularly important in this high-throughput environment.”
CLG selected Agilent’s genome-wide CGH+SNP microarrays for their capability, in a predictable high-throughput environment, to detect amplifications, deletions and cell line clonality with high sensitivity. CLG will use FISH assays to confirm aberrations identified down to the single-cell level. This approach provides a robust, best-in-class means of characterizing genome integrity and purity.
For cancer cell line characterization, CLG will offer array CGH (aCGH) services as it is able to simultaneously detect a large number of anomalies more accurately, with higher sensitivity, and with better coverage than traditional cytogenetics. In addition, when using aCGH, CLG can offer a faster turnaround time to customers.
After testing more than 15,000 stem cell lines, CLG found that 20 percent showed aneuploidy, and 60 to 70 percent of those were mosaic. Most significantly, the cells harboring genomic anomalies can have a proliferative advantage and overtake the culture, compromising the validity of study data and resulting in the loss of samples, time and funds.
“Collaborating with Agilent on custom microarray and SureFISH probe solutions gives us the most flexibility to innovate and expand our services,” said Rob Herrera, CEO and president, Cell Line Genetics. “For example, we can fortify our arrays in regions that we have identified as ‘integrity critical’ for even greater sensitivity. It allows us to easily design proprietary arrays and assays to support our customer’s research and translational needs.”
About Agilent in Genomics
Agilent is a global leader in target enrichment for next-generation sequencing and genomic microarrays. The Agilent SureSelect and HaloPlex target-enrichment systems enable researchers to easily choose which segments of a genome to sequence, avoiding the time and expense needed to sequence the entire genome. HaloPlex offers a same-day sample-to-sequencer workflow; SureSelect can accurately capture whole exomes and whole methylomes in a single reaction. These are just two products arising from Agilent’s expertise in synthesizing custom complex mixtures of long oligonucleotides gained in microarray manufacturing. Additional product lines built on this core technology include microarrays for genome-wide measurement of gene expression and for comparative genomics hybridization, as well as SureFISH, a highly specific and sensitive product line for oligonucleotide fluorescent in situ hybridization. In addition to oligonucleotide-based products, Agilent offers a microfluidic bioanlyzer to measure sample quality, and a full set of reagents, hardware, methods and bioinformatics software for genomic experiments.
For more information on Agilent’s complete line of Genomics solutions, visit: www.chem.agilent.com/en-US/Solutions/Genomics/Pages/default.aspx.
About Cell Line Genetics, Inc.
Cell Line Genetics, Inc. is a leading provider of Quality Assurance services and products for the Regenerative Medicine market. The company focuses on ensuring the genetic integrity and authentication of adult and pluripotent stem cell lines for research, preclinical and clinical studies. Headquartered in Madison, Wisconsin, and with offices in New York City, clients include leading universities, research institutes, biotechnology and pharmaceutical companies.
About Agilent Technologies
Agilent Technologies Inc. (NYSE: A) is the world’s premier measurement company and a technology leader in chemical analysis, life sciences, diagnostics, electronics and communications. The company’s 20,600 employees serve customers in more than 100 countries. Agilent had revenues of $6.8 billion in fiscal 2013. Information about Agilent is available at www.agilent.com.
On Sept. 19, 2013, Agilent announced plans to separate into two publicly traded companies through a tax-free spinoff of its electronic measurement business. The new company is named Keysight Technologies, Inc. The separation is expected to be completed in early November 2014.
NOTE TO EDITORS: Further technology, corporate citizenship and executive news is available at www.agilent.com/go/news.